Physician profile
Andrew Bensinger
NPI 1164953667
$5,025.41
in general payments reported to CMS, 2019-2025
25 companies · $2,184 in 2025
The $2,184 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,089 · 2024: $1,752 · 2025: $2,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,025.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,068.34 | 2023-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $521.10 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Gilead Sciences, INC. | $501.34 | 2023-2025 | Epclusa, Livdelzi |
| Cook Medical LLC | $386.05 | 2023-2025 | Hemospray, Litho 150 |
| Ardelyx, INC. | $353.32 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $309.06 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $274.65 | 2023-2025 | Ocaliva |
| Qol Medical, LLC | $203.50 | 2023-2025 | Sucraid, Sucraid |
| Celltrion USA INC. | $172.10 | 2024-2025 | Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $148.04 | 2023-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $146.98 | 2024-2025 | Tremfya, Stelara |
| Lilly USA, LLC | $145.74 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $114.25 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $109.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $88.37 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $86.44 | 2024 | |
| Celgene Corporation | $80.03 | 2023-2024 | Zeposia |
| Pfizer INC. | $77.52 | 2023-2025 | |
| Meridian Bioscience INC. | $72.11 | 2024 | |
| Braintree Laboratories, INC. | $68.04 | 2025 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $22.83 | 2025 | Iqirvo |
| Shield Therapeutics INC | $22.67 | 2024 | |
| Daiichi Sankyo INC. | $21.28 | 2023 | Injectafer |
| Merck Sharp & Dohme LLC | $17.05 | 2024 | Dificid |
| Fresenius Kabi USA, LLC | $15.58 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bensinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.